Page last updated: 2024-10-29

isoniazid and AIDS Seroconversion

isoniazid has been researched along with AIDS Seroconversion in 56 studies

Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).

Research Excerpts

ExcerptRelevanceReference
"Although antiretroviral therapy (ART) can avert tuberculosis (TB) incidence among human immunodeficiency virus (HIV) infected patients, the concomitant use of ART with isoniazid (INH) has a paramount effect."8.12Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia. ( Adem, M; Bayleyegn, B; Geremew, D; Geremew, H; Tamir, M; Tegene, B, 2022)
"The aims of this study were to (1) identify trends and risk factors for mycobacterial disease and (2) determine the effect of expanded access to isoniazid chemoprophylaxis on tuberculosis incidence."5.08Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. ( Astemborski, J; Bonds, M; Galai, N; Graham, NM; Nelson, KE; Rizzo, RT; Sheeley, L; Vlahov, D, 1996)
"Although antiretroviral therapy (ART) can avert tuberculosis (TB) incidence among human immunodeficiency virus (HIV) infected patients, the concomitant use of ART with isoniazid (INH) has a paramount effect."4.12Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia. ( Adem, M; Bayleyegn, B; Geremew, D; Geremew, H; Tamir, M; Tegene, B, 2022)
"A switch of continuation phase tuberculosis (TB) treatment regimen from Ethambutol (E) and Isoniazid (H) combination for 6 months (6EH) to Rifampicin (R) and Isoniazid (H) combination for 4 months (4RH) was recommended."3.83Tuberculosis treatment outcomes of six and eight month treatment regimens in districts of Southwestern Ethiopia: a comparative cross-sectional study. ( Asres, A; Deressa, W; Jerene, D, 2016)
"Isoniazide preventive therapy (IPT) is given to individuals with latent infection of tuberculosis (TB) to prevent the progression to active disease."3.77Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia. ( Biadgilign, S; Deribew, A; Mindachew, M; Tessema, F, 2011)
" Peak drug exposure to isoniazid was lower in patients with diarrhea."3.69Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. ( Cameron, DW; Gallicano, K; Garber, G; Oliveras, L; Rachlis, A; Sahai, J; Seguin, I; Swick, L; Tailor, S; Walker, S, 1997)
" We investigated the incidence of adverse events and cure rates according to HIV status for patients receiving standard TB therapy in the trial."2.90Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status. ( Crook, AM; Dawson, R; Diacon, AH; Gillespie, SH; McHugh, TD; Mendel, CM; Meredith, SK; Mohapi, L; Murphy, ME; Nunn, AJ; Phillips, PPJ; Singh, KP; Spigelman, M; Tweed, CD, 2019)
"Prophylaxis against tuberculosis has been recognized as important for preventing clinical forms of tuberculosis, mainly in HIV positive patients."2.73[Effectiveness of prophylaxis against tuberculosis in patients infected with HIV]. ( Arbeláez, A; Arbeláez, MP; Arias, SL; Betancourt, G; Gómez, RD; Nagles, J; Peláez, LM; Rojas, C; Velásquez, G; Vélez, L, 2007)
"Optimum treatment of tuberculosis in persons with human immunodeficiency virus (HIV) infection is still being defined."2.38Failure of therapy for tuberculosis in human immunodeficiency virus infection. ( Nolan, CM, 1992)
"Tuberculosis is on the increase in the United States, so physicians would be prudent to renew familiarity with the disease."2.38Tuberculosis makes a comeback. Giving and interpreting the Mantoux test. ( Dickensheets, DL, 1989)
"All grade 3 & 4 adverse events (AEs) and their relationship to treatment for patients who had taken at least one dose of therapy in the REMoxTB clinical trial were recorded."1.48Toxicity associated with tuberculosis chemotherapy in the REMoxTB study. ( Amukoye, EI; Crook, AM; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; McHugh, TD; Mendel, CM; Meredith, SK; Murphy, ME; Murthy, SE; Nunn, AJ; Phillips, PPJ; Singh, KP; Spigelman, M; Tweed, CD; Wills, GH, 2018)
"Half the recurrences occurred in the first year since completing treatment."1.38The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting. ( Crampin, AC; French, N; Glynn, JR; Houben, RM; Mboma, S; Mpunga, J; Mwaungulu, L; Mwaungulu, NJ; Mwenibabu, M; Mzemba, T, 2012)
"Major adverse reactions to antituberculosis drugs can cause significant morbidity, and compromise treatment regimens for tuberculosis (TB)."1.32Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. ( Menzies, D; Parisien, I; Pelletier, M; Rocher, I; Valiquette, C; Yee, D, 2003)
"Ethambutol was recovered from human urine quantitatively and stable for a period of at least one week in urine stored at -20 degrees C."1.32Standardization of the method for estimation of ethambutol in pharmaceutical preparations and biological fluid. ( Bhagavathy, S; Gayathri, TN; Gurumurthy, P; Venkatesan, P, 2004)
"The decision was analyzed for an intravenous drug abuser who may have been anergic, while tuberculin test status, race, and gender were varied."1.28Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis. ( Jordan, TJ; Lewit, EM; Montgomery, RL; Reichman, LB, 1991)

Research

Studies (56)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.79)18.7374
1990's27 (48.21)18.2507
2000's10 (17.86)29.6817
2010's14 (25.00)24.3611
2020's4 (7.14)2.80

Authors

AuthorsStudies
Geremew, D1
Geremew, H1
Tamir, M1
Adem, M1
Tegene, B1
Bayleyegn, B1
Sekayi, W1
Namyalo, E1
Namayanja, J1
Kungu, JM1
Tweed, CD2
Crook, AM3
Dawson, R2
Diacon, AH2
McHugh, TD4
Mendel, CM3
Meredith, SK3
Mohapi, L1
Murphy, ME2
Nunn, AJ4
Phillips, PPJ2
Singh, KP2
Spigelman, M2
Gillespie, SH4
Peetluk, LS1
Rebeiro, PF1
Cordeiro-Santos, M1
Kritski, A1
Andrade, BB1
Durovni, B1
Calvacante, S1
Arriaga, MB1
Turner, MM1
Figueiredo, MC1
Rolla, VC1
Sterling, TR1
Alemu, A1
Yesuf, A1
Zerihun, B1
Getu, M1
Worku, T1
Bitew, ZW1
Thindwa, D1
MacPherson, P1
Choko, AT1
Khundi, M1
Sambakunsi, R1
Ngwira, LG1
Kalua, T1
Webb, EL1
Corbett, EL1
Amukoye, EI1
Hanekom, M1
Murthy, SE1
Wills, GH1
Soborg, C1
Ruhwald, M1
Andersen, PH1
Ravn, P1
Murray, SR1
Pappas, F1
Phillips, PP2
Jindani, A1
Harrison, TS1
Churchyard, GJ1
Charalambous, S1
Hatherill, M1
Geldenhuys, H1
McIlleron, HM1
Zvada, SP1
Mungofa, S1
Shah, NA1
Zizhou, S1
Magweta, L1
Shepherd, J1
Nyirenda, S1
van Dijk, JH1
Clouting, HE1
Coleman, D1
Bateson, AL1
Butcher, PD1
Mitchison, DA2
Abdool Karim, SS1
Despotovic, A1
Savic, B1
Salemovic, D1
Ranin, J1
Jevtovic, D1
Asres, A1
Jerene, D1
Deressa, W1
Asiimwe, BB1
Ghebremichael, S1
Kallenius, G1
Koivula, T1
Joloba, ML1
Sar, B1
Keo, C1
Leng, C1
Saman, M1
Min, DC1
Chan, S1
Monchy, D1
Sarthou, JL1
Cohen, T1
Murray, M1
Wallengren, K1
Alvarez, GG1
Samuel, EY1
Wilson, D1
Khajotia, R1
Manthari, K1
Tripathy, S1
Anand, A1
Inamdar, V1
Manoj, MM1
Khillare, KM1
Datye, AS1
Iyer, R1
Kanoj, DM1
Thakar, M1
Kale, V1
Pereira, M1
Risbud, AR1
Mindachew, M1
Deribew, A1
Tessema, F1
Biadgilign, S1
Houben, RM1
Glynn, JR2
Mboma, S1
Mzemba, T1
Mwaungulu, NJ1
Mwaungulu, L1
Mwenibabu, M1
Mpunga, J1
French, N1
Crampin, AC1
Chakaya, JM1
Kibuga, D1
Ng'ang'a, L1
Githui, WA1
Mansoer, JR1
Gakiria, G1
Kwamanga, D1
Maende, J1
Yee, D1
Valiquette, C1
Pelletier, M1
Parisien, I1
Rocher, I1
Menzies, D1
Gurumurthy, P1
Gayathri, TN1
Bhagavathy, S1
Venkatesan, P1
Ramachandran, G1
Hemanth Kumar, AK1
Sarala, K1
Padmapriyadarsini, C1
Anitha, S1
Tharani, CB1
Kumaraswami, V1
Swaminathan, S1
Arbeláez, MP1
Arbeláez, A1
Gómez, RD1
Rojas, C1
Vélez, L1
Arias, SL1
Nagles, J1
Peláez, LM1
Betancourt, G1
Velásquez, G1
Masobe, P1
Lee, T1
Price, M1
Hawken, M1
Nunn, P1
Gathua, S1
Brindle, R1
Godfrey-Faussett, P1
Githui, W1
Odhiambo, J1
Batchelor, B1
Gilks, C1
Morris, J1
Chintu, C1
Bhat, G1
Luo, C1
Raviglione, M1
Diwan, V1
Dupont, HL1
Zumla, A1
Trautmann, M1
Ruhnke, M1
Held, T1
Weinke, T1
Pape, JW1
Jean, SS1
Ho, JL1
Hafner, A1
Johnson, WD1
Kennedy, N1
Fox, R1
Kisyombe, GM1
Saruni, AO1
Uiso, LO1
Ramsay, AR1
Ngowi, FI1
Neville, K1
Bromberg, A1
Bromberg, R1
Bonk, S1
Hanna, BA1
Rom, WN1
Schürmann, D1
Bergmann, F1
Jautzke, G1
Fehrenbach, J1
Mauch, H1
Ruf, B1
Delaney, V1
Sumrani, N1
Hong, JH1
Sommer, B1
Kassim, S1
Sassan-Morokro, M1
Ackah, A1
Abouya, LY1
Digbeu, H1
Yesso, G1
Coulibaly, IM1
Coulibaly, D1
Whitaker, PJ1
Doorly, R1
Brook, MG1
Miller, RF1
Suwanagool, S1
Chuenarom, V1
Pechthanon, L1
Sonjai, A1
Leelarasamee, A1
Pathrakom, C1
Ausina, V1
Graham, NM1
Galai, N1
Nelson, KE1
Astemborski, J1
Bonds, M1
Rizzo, RT1
Sheeley, L1
Vlahov, D1
Sahai, J1
Gallicano, K1
Swick, L1
Tailor, S1
Garber, G1
Seguin, I1
Oliveras, L1
Walker, S1
Rachlis, A1
Cameron, DW1
Bock, NN1
Metzger, BS1
Tapia, JR1
Blumberg, HM1
Topley, JM1
Bamber, S1
Coovadia, HM1
Corr, PD1
Snyder, DC1
Paz, EA1
Mohle-Boetani, JC1
Fallstad, R1
Black, RL1
Chin, DP1
Warndorff, DK1
Yates, M1
Ngwira, B1
Chagaluka, S1
Jenkins, PA1
Drobniewski, F1
Pönnighaus, JM1
Fine, PE1
Perlman, DC1
Gourevitch, MN1
Trinh, C1
Salomon, N1
Horn, L1
Des Jarlais, DC1
Kingston, M1
Childs, K1
Carlin, E1
Veeken, H1
Bermejo, A1
Nolan, CM1
Shafer, RW1
Chirgwin, KD1
Glatt, AE1
Dahdouh, MA1
Landesman, SH1
Suster, B1
Figg, WD1
Jordan, TJ1
Lewit, EM1
Montgomery, RL1
Reichman, LB1
Dickensheets, DL1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening[NCT00864383]Phase 31,931 participants (Actual)Interventional2008-01-31Completed
Using Biomarkers to Predict TB Treatment Duration[NCT02821832]Phase 2946 participants (Actual)Interventional2017-06-21Active, not recruiting
A Prospective, Randomized Controlled Study for the Efficacy and Safety of the Substitution of Pyrazinamide and Ethambutol With Moxifloxacin During the Intensive Phase of Treatment of Pulmonary Tuberculosis[NCT04187469]286 participants (Anticipated)Interventional2020-03-01Not yet recruiting
Z 31411 - The Effect of Xpert MTB/RIF on Patient Health Outcomes and Empirical TB Treatment Among Persons Living With HIV/AIDS: A Parallel-Group Prospective Cohort Study Under Real-World Conditions in Lusaka, Zambia[NCT02729532]776 participants (Actual)Observational2016-06-22Completed
Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa[NCT05633056]360 participants (Anticipated)Interventional2023-02-28Not yet recruiting
Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis[NCT00376012]Phase 3300 participants (Actual)Interventional2001-02-28Active, not recruiting
TB Treatment Support Tools: Refinement and Evaluation of an Interactive Mobile App and Direct Adherence Monitoring on TB Treatment Outcomes[NCT04221789]555 participants (Actual)Interventional2020-11-17Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Combined Failure of Bacteriological Cure and Relapse as Defined by Culture Using Liquid Media (Mycobacteria Growth Indicator Tube-MGIT).

The secondary analysis of efficacy outcome was the proportion of patients who had bacteriologically or clinically defined failure or relapse within 18 months after randomization (a composite unfavorable outcome) based on MGIT. Culture-negative status was defined as two negative-culture results at different visits without an intervening positive result. The date of culture-negative status was defined as the date of the first negative-culture result. This status continued until there were two positive cultures, without an intervening negative culture, or until there was a single positive culture that was not followed by two negative cultures. Relapse strains were those shown to be identical on 24-locus Mycobacterial interspersed repetitive units (MIRU) analysis. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)

Interventionparticipants with failure or relapse (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)65
Regimen 2 - 2MHRZ/2MHR98
Regimen 3 - 2EMRZ/2MR131

Combined Failure of Bacteriological Cure and Relapse Within One Year of Completion of Therapy as Defined by Culture Using Solid Media (Lowenstein-Jensen - LJ).

The primary efficacy outcome was the proportion of patients who had bacteriologically or clinically defined failure or relapse within 18 months after randomization (a composite unfavorable outcome). Culture-negative status was defined as two negative-culture results at different visits without an intervening positive result. The date of culture-negative status was defined as the date of the first negative-culture result. This status continued until there were two positive cultures, without an intervening negative culture, or until there was a single positive culture that was not followed by two negative cultures. Relapse strains were those shown to be identical on 24-locus Mycobacterial interspersed repetitive units (MIRU) analysis. For the final 18 month study visit when both L-J samples were contaminated or missing, if the subject could not be brought back, liquid medium culture results were used in place of solid medium culture results. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)

Interventionparticipants with failure or relapse (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)43
Regimen 2 - 2MHRZ/2MHR78
Regimen 3 - 2EMRZ/2MR105

Number of Patients Who Are Culture Negative (Liquid MGIT Culture)

Number of patients who are TB MGIT culture negative at 8 weeks. (NCT00864383)
Timeframe: 8 weeks

Interventionparticipants who are culture negative (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)235
Regimen 2 - 2MHRZ/2MHR274
Regimen 3 - 2EMRZ/2MR260

Number of Patients Who Are Culture Negative (Solid LJ Culture)

Number of patients who are TB LJ culture negative at 8 weeks. (NCT00864383)
Timeframe: 8 weeks

Interventionparticipants who are culture negative (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)352
Regimen 2 - 2MHRZ/2MHR394
Regimen 3 - 2EMRZ/2MR401

Number of Patients With Grade 3 or 4 Adverse Events (Using a Modified Division of Acquired Immunodeficiency Syndrome National Institute of Allergy and Infectious Diseases [DAIDS] Scale of Adverse Event Reporting)

The number of participants includes all patients who had at least one grade 3 or 4 adverse event. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)

Interventionparticipants with Grade 3 or 4 AEs (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)123
Regimen 2 - 2MHRZ/2MHR127
Regimen 3 - 2EMRZ/2MR111

Sensitivity Analyses Assuming All Losses to Follow-up and Non-tuberculous Deaths Have a Favourable Outcome Using Solid (L-J) Media.

"Sensitivity Analysis of Primary Efficacy Results of All Randomized Subjects Imputing Favorable for Missing Outcomes. Analysis is the number of subjects with an unfavorable outcome. Favorable outcome is defined as the number of subjects with a negative TB culture status at 18 months (at or after 72 weeks), who had not already been classified as having an unfavorable outcome, and whose last positive TB culture result (isolated positive culture) was followed by at least two negative culture results." (NCT00864383)
Timeframe: 18 months

Interventionparticipants with unfavorable outcome (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)87
Regimen 2 - 2MHRZ/2MHR132
Regimen 3 - 2EMRZ/2MR132

Sensitivity Analysis Assuming All Losses to Follow-up and Non-tuberculous Deaths Have an Unfavorable Outcome Using Solid (L-J) Media.

"Sensitivity Analysis of Primary Efficacy Results of All Randomized Subjects Imputing Unfavorable for Missing Outcomes. Analysis is the number of subjects with an unfavorable outcome. Favorable outcome is defined as the number of subjects with a negative TB culture status at 18 months (at or after 72 weeks), who had not already been classified as having an unfavorable outcome, and whose last positive TB culture result (isolated positive culture) was followed by at least two negative culture results." (NCT00864383)
Timeframe: 18 months

Interventionparticipants with unfavorable outcome (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)172
Regimen 2 - 2MHRZ/2MHR219
Regimen 3 - 2EMRZ/2MR217

Time to First Culture Negative Sputum Sample (LJ Solid Media)

Culture negative for TB using LJ cultures. (NCT00864383)
Timeframe: 18 months

InterventionTime to culture negative status / weeks (Median)
Regimen 1 - 2EHRZ/4HR (Control Regimen)6.0
Regimen 2 - 2MHRZ/2MHR6.0
Regimen 3 - 2EMRZ/2MR6.0

Time to First Culture Negative Sputum Sample (MGIT Liquid Media)

(NCT00864383)
Timeframe: 18 months

InterventionTime to culture negative status / weeks (Median)
Regimen 1 - 2EHRZ/4HR (Control Regimen)11.9
Regimen 2 - 2MHRZ/2MHR8.0
Regimen 3 - 2EMRZ/2MR8.0

Comparison of the Rate of Treatment Success at 18 Months (After Treatment Initiation) Between Arms B and C

Estimation of the lower bound of a one-sided 95% confidence interval of the difference in success rates between arms B and C. If the lower bound is greater than -7%, this will be evidence that the treatment-shortening arm is not inferior to the standard duration arm. (NCT02821832)
Timeframe: 18 months

,,
InterventionParticipants (Count of Participants)
CuredConfirmed relapsesLate withdrawal, lost to follow-upProbable relapsesTreatment Failure
Arm A21751311
Arm B1211910
Arm C1179634

Reviews

5 reviews available for isoniazid and AIDS Seroconversion

ArticleYear
Complicated tuberculosis and residual disease.
    Immunobiology, 1994, Volume: 191, Issue:4-5

    Topics: HIV Seropositivity; Humans; Isoniazid; Recurrence; Risk Factors; Tuberculosis; Tuberculosis, Pulmona

1994
Prevention and management of tuberculosis in HIV positive patients living in countries with a low prevalence of Mycobacterium tuberculosis.
    Genitourinary medicine, 1996, Volume: 72, Issue:2

    Topics: Antitubercular Agents; Cross Infection; Emigration and Immigration; Ethambutol; HIV Seropositivity;

1996
The impact of the HIV epidemic on tuberculosis control programmes in developing countries.
    Tropical doctor, 1992, Volume: 22, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; BCG Vaccine; Child; Child, Preschool; Contraindications; Develop

1992
Failure of therapy for tuberculosis in human immunodeficiency virus infection.
    The American journal of the medical sciences, 1992, Volume: 304, Issue:3

    Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Drug Therapy, Combi

1992
Tuberculosis makes a comeback. Giving and interpreting the Mantoux test.
    Postgraduate medicine, 1989, Volume: 86, Issue:2

    Topics: Adult; Age Factors; False Negative Reactions; HIV Seropositivity; Humans; Hypersensitivity, Delayed;

1989

Trials

9 trials available for isoniazid and AIDS Seroconversion

ArticleYear
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.
    BMC pulmonary medicine, 2019, Aug-14, Volume: 19, Issue:1

    Topics: Adult; Antitubercular Agents; Ethambutol; Female; HIV Seropositivity; Humans; Incidence; Isoniazid;

2019
Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2018, 03-01, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Anti-Retroviral Agents; Antitubercular Agents; CD4 Lymphocyte Count; Female; HIV

2018
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, C

2014
[Effectiveness of prophylaxis against tuberculosis in patients infected with HIV].
    Biomedica : revista del Instituto Nacional de Salud, 2007, Volume: 27, Issue:4

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Cohort Studies; Comorbidity; Fe

2007
Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection.
    Lancet (London, England), 1993, Jul-31, Volume: 342, Issue:8866

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Drug Therapy, Comb

1993
Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.
    The American review of respiratory disease, 1993, Volume: 148, Issue:6 Pt 1

    Topics: Adult; Aged; Ciprofloxacin; Drug Therapy, Combination; Ethambutol; Female; HIV Seropositivity; HIV-1

1993
Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa.
    AIDS (London, England), 1995, Volume: 9, Issue:10

    Topics: Adolescent; Adult; Africa, Western; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercul

1995
Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
    Archives of internal medicine, 1996, Apr-22, Volume: 156, Issue:8

    Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antitubercular Agents; Female;

1996

Other Studies

42 other studies available for isoniazid and AIDS Seroconversion

ArticleYear
Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia.
    PloS one, 2022, Volume: 17, Issue:4

    Topics: Adult; Antitubercular Agents; Ethiopia; HIV Infections; HIV Seropositivity; Humans; Incidence; Isoni

2022
Prevalence and predictors of tuberculosis among HIV patients who completed isoniazid preventive therapy (IPT) at Reach out Mbuya community health initiative.
    Scientific reports, 2023, 10-16, Volume: 13, Issue:1

    Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; HIV; HIV Infections; HIV Seropositivity; Huma

2023
Lack of Weight Gain During the First 2 Months of Treatment and Human Immunodeficiency Virus Independently Predict Unsuccessful Treatment Outcomes in Tuberculosis.
    The Journal of infectious diseases, 2020, 04-07, Volume: 221, Issue:9

    Topics: Adult; Antitubercular Agents; Brazil; Ethambutol; Female; HIV Seropositivity; Humans; Isoniazid; Mal

2020
Incidence and determinants of tuberculosis among HIV-positive individuals in Addis Ababa, Ethiopia: A retrospective cohort study.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020, Volume: 95

    Topics: Adolescent; Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Disease-Free Survival; Ethio

2020
Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
    BMC infectious diseases, 2018, 07-11, Volume: 18, Issue:1

    Topics: Adult; Antitubercular Agents; Clinical Protocols; Ethambutol; Female; HIV Seropositivity; Humans; In

2018
6-year follow-up of 522 HIV-positive individuals screened for Mycobacterium tuberculosis infection in Denmark.
    The European respiratory journal, 2014, Volume: 44, Issue:2

    Topics: Cohort Studies; Communicable Disease Control; Denmark; Diagnostic Tests, Routine; Female; Follow-Up

2014
Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy.
    The New England journal of medicine, 2015, Aug-27, Volume: 373, Issue:9

    Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Female; HIV In

2015
Isoniazid-resistant Mycobacterium kansasii in an HIV-positive patient, and possible development of immune reconstitution inflammatory syndrome after initiation of highly active antiretroviral therapy: case report.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2016, Volume: 42

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; HIV Seropositivity; Humans; Imm

2016
Tuberculosis treatment outcomes of six and eight month treatment regimens in districts of Southwestern Ethiopia: a comparative cross-sectional study.
    BMC infectious diseases, 2016, 11-08, Volume: 16, Issue:1

    Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; Drug Therapy, Combination; Ethambutol; Ethiop

2016
Mycobacterium tuberculosis spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in peri-urban Kampala, Uganda.
    BMC infectious diseases, 2008, Jul-28, Volume: 8

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antibodies, Bacterial; Bacterial Typing Techniques;

2008
Anti-tuberculosis drug resistance and HIV co-infection in Phnom Penh, Cambodia.
    The Southeast Asian journal of tropical medicine and public health, 2009, Volume: 40, Issue:1

    Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Cambodia; HIV Infections; HIV Seroposi

2009
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
    PLoS medicine, 2010, Jun-22, Volume: 7, Issue:6

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte

2010
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
    PLoS medicine, 2010, Jun-22, Volume: 7, Issue:6

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte

2010
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
    PLoS medicine, 2010, Jun-22, Volume: 7, Issue:6

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte

2010
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.
    PLoS medicine, 2010, Jun-22, Volume: 7, Issue:6

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Drug Resistance, Bacte

2010
An apparently healthy young man with a peculiar-looking chest radiograph.
    Canadian family physician Medecin de famille canadien, 2011, Volume: 57, Issue:3

    Topics: Adult; Antibiotics, Antitubercular; Drug Therapy, Combination; Ethambutol; Fever; HIV Seropositivity

2011
Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India.
    The Indian journal of medical research, 2011, Volume: 133

    Topics: Adult; Antitubercular Agents; Communicable Disease Control; Directly Observed Therapy; Enzyme-Linked

2011
Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia.
    BMC public health, 2011, Dec-12, Volume: 11

    Topics: Adult; Aged; Antitubercular Agents; Cross-Sectional Studies; Ethiopia; Female; Forecasting; HIV Sero

2011
The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting.
    AIDS (London, England), 2012, Nov-13, Volume: 26, Issue:17

    Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; CD

2012
Tuberculosis re-treatment outcomes within the public service in Nairobi, Kenya.
    East African medical journal, 2002, Volume: 79, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag

2002
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
    American journal of respiratory and critical care medicine, 2003, Jun-01, Volume: 167, Issue:11

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug In

2003
Standardization of the method for estimation of ethambutol in pharmaceutical preparations and biological fluid.
    Indian journal of experimental biology, 2004, Volume: 42, Issue:1

    Topics: Antitubercular Agents; Chemistry, Clinical; Chromatography; Dose-Response Relationship, Drug; Ethamb

2004
Urine levels of rifampicin & isoniazid in asymptomatic HIV-positive individuals.
    The Indian journal of medical research, 2007, Volume: 125, Issue:6

    Topics: Adult; Antitubercular Agents; CD4-Positive T-Lymphocytes; Drug Administration Schedule; Drug Resista

2007
Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients--a least-cost analysis.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1995, Volume: 85, Issue:2

    Topics: Ambulatory Care; Computer Simulation; Cost of Illness; Costs and Cost Analysis; Feasibility Studies;

1995
Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya.
    Lancet (London, England), 1993, Aug-07, Volume: 342, Issue:8867

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitu

1993
Seroprevalence of human immunodeficiency virus type 1 infection in Zambian children with tuberculosis.
    The Pediatric infectious disease journal, 1993, Volume: 12, Issue:6

    Topics: Adolescent; AIDS-Related Opportunistic Infections; BCG Vaccine; Child; Child, Preschool; Drug Therap

1993
The third epidemic--multidrug-resistant tuberculosis.
    Chest, 1994, Volume: 105, Issue:1

    Topics: Adult; Age Factors; Comorbidity; Disease Outbreaks; Drug Resistance, Microbial; Ethambutol; Female;

1994
Acute and long-term efficacy of antituberculous treatment in HIV-seropositive patients with tuberculosis: a study of 36 cases.
    The Journal of infection, 1993, Volume: 26, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antitubercular Agents; Bisexuality; CD4-CD8 Ratio;

1993
Mycobacterial infections in renal allograft recipients.
    Transplantation proceedings, 1993, Volume: 25, Issue:3

    Topics: Drug Therapy, Combination; Ethambutol; HIV Seropositivity; Humans; Immunosuppressive Agents; Isoniaz

1993
A comparative study of tuberculin skin test reactivity between asymptomatic HIV-1 seropositive subjects and healthy volunteers.
    Asian Pacific journal of allergy and immunology, 1995, Volume: 13, Issue:2

    Topics: Adult; Antitubercular Agents; Female; HIV Seropositivity; HIV-1; Humans; Isoniazid; Male; Thailand;

1995
[Multidrug-resistant tuberculosis. Remarks and reflections on a controversial subject of current utmost importance].
    Medicina clinica, 1996, Jan-13, Volume: 106, Issue:1

    Topics: Antitubercular Agents; Drug Resistance, Multiple; HIV Infections; HIV Seronegativity; HIV Seropositi

1996
Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection.
    Annals of internal medicine, 1997, Aug-15, Volume: 127, Issue:4

    Topics: Adult; Aged; Antitubercular Agents; Case-Control Studies; Diarrhea; Ethambutol; Female; HIV Infectio

1997
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1998, Volume: 2, Issue:1

    Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Drug Admi

1998
A tuberculin screening and isoniazid preventive therapy program in an inner-city population.
    American journal of respiratory and critical care medicine, 1999, Volume: 159, Issue:1

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Female; HIV Seropositivity;

1999
Tuberculous meningitis and co-infection with HIV.
    Annals of tropical paediatrics, 1998, Volume: 18, Issue:4

    Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Child, Preschool; HIV Seronegat

1998
Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness.
    American journal of respiratory and critical care medicine, 1999, Volume: 160, Issue:1

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cost-Benefit Analysis; Drug The

1999
Trends in antituberculosis drug resistance in Karonga District, Malawi, 1986-1998.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2000, Volume: 4, Issue:8

    Topics: Adult; Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Female; HIV Seropositivity; Hu

2000
CDC changing position on anergy testing, therapy. Centers for Disease Control and Prevention.
    AIDS alert, 1997, Volume: 12, Issue:10

    Topics: Antitubercular Agents; Clinical Protocols; HIV Seropositivity; Humans; Isoniazid; Risk Factors; Tube

1997
Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program.
    Journal of urban health : bulletin of the New York Academy of Medicine, 2001, Volume: 78, Issue:3

    Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cost-Benefit Analys

2001
Adverse reaction to antimycobacterials administered as a combination tablet with no reaction to the same drugs in isolation.
    Sexually transmitted infections, 2001, Volume: 77, Issue:5

    Topics: Adult; Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; HIV Seropositivity; Huma

2001
Transmission of multidrug-resistant tuberculosis among immunocompromised persons in a correctional system--New York, 1991.
    MMWR. Morbidity and mortality weekly report, 1992, Jul-17, Volume: 41, Issue:28

    Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Ethionamide; HIV Seropositivity; Huma

1992
From the Centers for Disease Control. Transmission of multidrug-resistant tuberculosis among immunocompromised persons, correctional system--New York, 1991.
    JAMA, 1992, Aug-19, Volume: 268, Issue:7

    Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Ethionamide; HIV Seropositivity; Huma

1992
HIV prevalence, immunosuppression, and drug resistance in patients with tuberculosis in an area endemic for AIDS.
    AIDS (London, England), 1991, Volume: 5, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; CD4-Positive T-Lymphocytes; Drug Resist

1991
Peripheral neuropathy in HIV patient after isoniazid therapy initiated.
    DICP : the annals of pharmacotherapy, 1991, Volume: 25, Issue:1

    Topics: Adult; HIV Seropositivity; Humans; Isoniazid; Male; Peripheral Nervous System Diseases

1991
Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis.
    JAMA, 1991, Jun-12, Volume: 265, Issue:22

    Topics: Adult; Chemical and Drug Induced Liver Injury; Decision Trees; HIV Infections; HIV Seropositivity; H

1991